Silence Therapeutics (SLNCF) Invested Capital (2019 - 2025)
Historic Invested Capital for Silence Therapeutics (SLNCF) over the last 7 years, with Q3 2025 value amounting to $74.1 million.
- Silence Therapeutics' Invested Capital fell 3968.98% to $74.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.1 million, marking a year-over-year decrease of 3968.98%. This contributed to the annual value of $134.0 million for FY2024, which is 53333.0% up from last year.
- As of Q3 2025, Silence Therapeutics' Invested Capital stood at $74.1 million, which was down 3968.98% from $94.2 million recorded in Q2 2025.
- Silence Therapeutics' 5-year Invested Capital high stood at $157.2 million for Q1 2024, and its period low was $5.4 million during Q1 2022.
- Moreover, its 5-year median value for Invested Capital was $29.5 million (2022), whereas its average is $63.6 million.
- In the last 5 years, Silence Therapeutics' Invested Capital soared by 82593.98% in 2024 and then plummeted by 3968.98% in 2025.
- Quarter analysis of 5 years shows Silence Therapeutics' Invested Capital stood at $11.5 million in 2021, then soared by 125.26% to $25.9 million in 2022, then decreased by 18.26% to $21.2 million in 2023, then skyrocketed by 533.33% to $134.0 million in 2024, then plummeted by 44.74% to $74.1 million in 2025.
- Its last three reported values are $74.1 million in Q3 2025, $94.2 million for Q2 2025, and $112.7 million during Q1 2025.